|
Simcyp
pbpk models simcyp Pbpk Models Simcyp, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/simcyp+pbpk+model/pm30298439-259-1-14 Average 90 stars, based on 1 article reviews
pbpk models simcyp - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
r/s enantiomers warfarin pbpk model R/S Enantiomers Warfarin Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/pbpk+models+of+warfarin+enantiomers/pm32060909-2992-4-14 Average 90 stars, based on 1 article reviews
r/s enantiomers warfarin pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
pbpk model simcyp version 19 Pbpk Model Simcyp Version 19, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/13+compartment+full+pbpk+model+simcyp++population+based+simulator+version+12+1/pm37376778-68-6-9 Average 90 stars, based on 1 article reviews
pbpk model simcyp version 19 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
midazolam pbpk model Midazolam Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/midazolam+pbpk+model/pmc09291816__CPT___110___1547___s001-115-9-13 Average 90 stars, based on 1 article reviews
midazolam pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
based pbpk model Based Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/full+pbpk+model/pmc07065849-343-47-48 Average 90 stars, based on 1 article reviews
based pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
physiologically based pharmacokinetic (pbpk) model simcyp simulator version 21 Physiologically Based Pharmacokinetic (Pbpk) Model Simcyp Simulator Version 21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/physiologically+based+pharmacokinetic++pbpk++model/pmc12034907-55-16-18 Average 90 stars, based on 1 article reviews
physiologically based pharmacokinetic (pbpk) model simcyp simulator version 21 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
neonatal physiologically-based pharmacokinetic (pbpk) model of sublingual buprenorphine Neonatal Physiologically Based Pharmacokinetic (Pbpk) Model Of Sublingual Buprenorphine, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/neonatal+physiologically+based+pharmacokinetic++pbpk++model+of+sublingual+buprenorphine/pm34679189-3-14-19 Average 90 stars, based on 1 article reviews
neonatal physiologically-based pharmacokinetic (pbpk) model of sublingual buprenorphine - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
probenecid pbpk model Probenecid Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/probenecid+pbpk+model/pm37620246-83-1-7 Average 90 stars, based on 1 article reviews
probenecid pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
pbk model ![]() Pbk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/pbpk+model+for+olz/pmc11094581-1175-68-55 Average 90 stars, based on 1 article reviews
pbk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
pbpk model of da disposition in humans ![]() Pbpk Model Of Da Disposition In Humans, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/adult+pbpk+model/pmc05776359-188-1-16 Average 90 stars, based on 1 article reviews
pbpk model of da disposition in humans - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
pemigatinib pbpk model ![]() Pemigatinib Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/imatinib+pbpk+model/pmc09286713-107-3-25 Average 90 stars, based on 1 article reviews
pemigatinib pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
intravenous tramadol retrograde pbpk model ![]() Intravenous Tramadol Retrograde Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pbpk+models+simcyp/intravenous+tramadol+retrograde+pbpk+model/pmc04627449-6-2-10 Average 90 stars, based on 1 article reviews
intravenous tramadol retrograde pbpk model - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: EFSA Journal
Article Title: Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites
doi: 10.2903/j.efsa.2024.8759
Figure Lengend Snippet: Overview of identified major uncertainties related to metabolism and excretion processes of the available PBK model for acetamiprid.
Article Snippet: However, as the combination of these different uncertain model parameters will affect the PBK model predictions for the internal dosimetry and urinary levels of both acetamiprid and IM‐2‐1, i.e. the critical PBK model outcomes that are required to answer the assessment question 1b, the WG considered that a translation of the available
Techniques: Radioactivity, Selection, In Vivo
Journal: EFSA Journal
Article Title: Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites
doi: 10.2903/j.efsa.2024.8759
Figure Lengend Snippet: Schematic overview of interrelation of identified uncertainties related to metabolism and excretion processes of acetamiprid and IM‐2‐1 in the available PBK model for acetamiprid. The PBK model parameter values chosen for the kinetic processes related to U1, U2 and U4 impact on predicted internal and urinary acetamiprid concentrations (U6). The PBK model parameter values chosen for the kinetic processes related to U1–U5 impact on predicted internal and urinary IM‐2‐1 concentrations (U7).
Article Snippet: However, as the combination of these different uncertain model parameters will affect the PBK model predictions for the internal dosimetry and urinary levels of both acetamiprid and IM‐2‐1, i.e. the critical PBK model outcomes that are required to answer the assessment question 1b, the WG considered that a translation of the available
Techniques:
Journal: Drug Metabolism and Disposition
Article Title: Toxicokinetics and Physiologically Based Pharmacokinetic Modeling of the Shellfish Toxin Domoic Acid in Nonhuman Primates
doi: 10.1124/dmd.117.078485
Figure Lengend Snippet: Summary of input parameter values for DA PBPK model in monkeys
Article Snippet: A
Techniques: Molecular Weight
Journal: Drug Metabolism and Disposition
Article Title: Toxicokinetics and Physiologically Based Pharmacokinetic Modeling of the Shellfish Toxin Domoic Acid in Nonhuman Primates
doi: 10.1124/dmd.117.078485
Figure Lengend Snippet: Observed and predicted toxicokinetic parameters of DA in monkeys after single intravenous doses Observed values are reported as geometric mean ± S.D. The predicted population representative values simulated using the PBPK model are shown together with the predicted range of values included in parentheses.
Article Snippet: A
Techniques:
Journal: Drug Metabolism and Disposition
Article Title: Toxicokinetics and Physiologically Based Pharmacokinetic Modeling of the Shellfish Toxin Domoic Acid in Nonhuman Primates
doi: 10.1124/dmd.117.078485
Figure Lengend Snippet: Observed and predicted toxicokinetic parameters of DA in monkeys after single oral doses Observed values are reported as geometric mean ± S.D except for C max which is the arithmetic mean and S.D. The predicted population representative value simulated using the PBPK model is shown together with the predicted range of values included in parentheses.
Article Snippet: A
Techniques:
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Summary of key input parameters for the pemigatinib physiologically based pharmacokinetic model
Article Snippet: In addition, the
Techniques: Molecular Weight, Solubility
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Simulated and observed mean plasma concentration–time profiles of pemigatinib: (a) single oral dose of 4.5 mg pemigatinib in the absence of itraconazole, (b) single oral dose of 13.5 mg pemigatinib in the absence of rifampin, (c) multiple oral dose (6–20 mg) of pemigatinib in patients with cancer. Simulated mean = red solid line; simulated 5% and 95% = red dashed line; observed = black circle
Article Snippet: In addition, the
Techniques: Clinical Proteomics, Concentration Assay
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Predicted and observed pemigatinib exposures (geometric mean) for single oral doses of 4.5 or 13.5 mg pemigatinib in healthy volunteers and multiple oral doses of pemigatinib in patients with cancer
Article Snippet: In addition, the
Techniques:
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Predicted and observed pemigatinib C max and AUC ratios following a single oral dose of 9 mg pemigatinib tablets with and without itraconazole or rifampin administration
Article Snippet: In addition, the
Techniques:
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Simulated and observed plasma concentration–time profiles of a single oral dose of 9 mg pemigatinib when coadministered with (a) itraconazole (200 mg once daily [q.d.]) and (b) rifampin (600 mg q.d.)
Article Snippet: In addition, the
Techniques: Clinical Proteomics, Concentration Assay
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Simulated pemigatinib drug–drug interactions with various CYP3A4 inhibitors or inducers
Article Snippet: In addition, the
Techniques: Inhibition
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
doi: 10.1002/psp4.12805
Figure Lengend Snippet: Observed and simulated AUC and C max ratios of a single dose of 13.5 mg pemigatinib with various cytochrome P450 3A4 inhibitors and inducers. AUC, area under the plasma drug concentration–time curve; C max , maximum plasma drug concentration; CI, confidence interval; DDI, drug–drug interaction
Article Snippet: In addition, the
Techniques: Clinical Proteomics, Concentration Assay
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: A one-compartment linear disposition model was used to fit the parent drug. An additional compartment for the ODT metabolite was linked to the central compartment by its formation clearance (CLP2M). Urinary excretion of tramadol (CLPR) was estimated based on the total amount of tramadol found in urine (UR). ODT moiety-related clearance (CLM) and volume (VM) were estimated based on the ODT plasma concentrations and total ODT amount found in urine (UR); CLPO other clearance parent
Article Snippet: An intravenous
Techniques: Clinical Proteomics
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Criteria by which CYP contributions in the retrograde model are assessed. CYP2D6 involvement was estimated by comparing hepatic clearance fold increase from PM to EM between predictions and in vivo. CYP2B6-CYP3A4 involvement was estimated by comparing AUCinduced/AUCcontrol ratios between predictions and observations
Article Snippet: An intravenous
Techniques: In Vivo, Control
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: DDI clinical trial simulation of tramadol and rifampicin to assess the CYP2B6-3A4 contribution. The figure depicts the results of 100 trial simulations mimicking the original trial, when CYP2B6-3A4 contributions are assumed to be 10–42%, respectively. Black horizontal lines represent the in vivo observed ratio of AUC geo means (solid) and 90% confidence limits (dashed). The solid red line represents the average ratio of simulated AUC geo means. Since the solid black line still is in the 90% confidence region (grayed area) of the simulated ratio, we assume that CYP2B6 contribution should be between 0 and 10%
Article Snippet: An intravenous
Techniques: In Vivo
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Fractional Activities of Pediatric Tramadol Metabolism (Relative to Adult Activity) for the Formation of ODT and NDT Are Provided, Together with Those for the Probe Substrates DEX and MDZ Representative of CYP2D6 and CYP3A4 Activity, Respectively
Article Snippet: An intravenous
Techniques: Activity Assay
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Maturation of total tramadol clearance as a function of PMA (left) and body weight (right). PBPK predictions, represented as blue dots, are compared to in vivo maturation functions: Hill model (19) (black), exponential model (20) (red), and WinNonlin fits (light brown)
Article Snippet: An intravenous
Techniques: In Vivo
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Maturation of CYP2D6 tramadol clearance as a function of PMA (left) and body weight (right). PBPK predictions, represented as blue dots, are compared to in vivo maturation functions: Hill model (19) (black), exponential model (20) (red), and WinNonlin fits (light brown)
Article Snippet: An intravenous
Techniques: In Vivo
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Maturation of renal tramadol clearance as a function of PMA (left) and body weight (right). PBPK predictions, represented as blue dots, are compared to WinNonlin fits (light brown)
Article Snippet: An intravenous
Techniques:
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Maturation of total tramadol clearance as a function of PMA. Comparing the PBPK predictions (blue dots) to the in vivo Hill maturation function (red dots) reveals that the largest underprediction in total clearance is manifested between 2 and 13 years (100–650 weeks) of age
Article Snippet: An intravenous
Techniques: In Vivo
Journal: The AAPS Journal
Article Title: Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
doi: 10.1208/s12248-015-9803-z
Figure Lengend Snippet: Maturation of CYP2D6 tramadol clearance as a function of PMA. Comparing the PBPK predictions (blue dots) to the in vivo Hill maturation function (red dots) reveals that the largest underprediction in CYP2D6 clearance is manifested between 2 and 13 years (100–650 weeks) of age
Article Snippet: An intravenous
Techniques: In Vivo